Calcimedica announces presentation of data from a preclinical study of auxora in acute kidney injury at the 29th international aki & crrt conference

Preclinical data show that therapeutic treatment with auxora in a rat model of aki improves kidney function as measured by glomerular filtration rate la jolla, calif. , feb. 28, 2024 /prnewswire/ -- calcimedica inc. (calcimedica or the company) (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that data from its most recent preclinical study of auxora™ (zegocractin) in acute kidney injury (aki) will be presented in a poster and oral presentation at the 29th international acute kidney injury and continuous renal replacement therapy conference (aki & crrt) being held march 12-15, 2024 in san diego, ca.
CALC Ratings Summary
CALC Quant Ranking